Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 10Nivolumab 5Gemcitabine 4durvalumab 3Specimen Handling 3Sirolimus 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cryosurgery 3Cisplatin 3Blood Specimen Collection 3tremelimumab 2temsirolimus 2pertuzumab 2pegilodecakin 2enzalutamide 2cabozantinib 2alvocidib 2Vorinostat 2Trastuzumab 2Ritonavir 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Interleukin-2 2Cyclophosphamide 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × IT-101 × Dermatologic × Clear all
NCT00333502 2020-05-28

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Lumos Pharma

Phase 1/2 Completed
62 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡